AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Please note
: Importing new articles from Word documents is currently unavailable. We are working on fixing this issue soon and apologize for any inconvenience.
Yoshiki Tanaka
Public Documents
1
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with at...
Naoto Saito
and 13 more
April 01, 2022
An 81-year-old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5-month progression-free survival. Atez/Bev might exhibit efficacy for CHC patients.